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Abstract
Background: Platinum-based chemotherapy is the cornerstone of treatment of advanced non-small-cell lung cancer
(NSCLC) patients, but the efﬁcacy of adding cisplatin to single-agent chemotherapy remains to be demonstrated in
prospective phase III trials dedicated to elderly patients. Furthermore, the superiority of cisplatin/pemetrexed over
cisplatin/gemcitabine in non-squamous NSCLC has not been conﬁrmed prospectively. We present the rationale and
design of two open-label, multicenter, randomized phase III trials for elderly patients with advanced NSCLC: Multi-
center Italian Lung cancer in the Elderly Study (MILES)-3 and MILES-4. The aim is to evaluate the efﬁcacy of adding
cisplatin to single-agent chemotherapy (both trials) and the efﬁcacy of pemetrexed versus gemcitabine in non-
squamous tumors (MILES-4). Patients and Methods: Both trials are dedicated to ﬁrst-line therapy of patients older
than 70 years with advanced NSCLC, ECOG performance status 0-1. In the MILES-3 trial, patients are randomized in a
1:1 ratio to gemcitabine or cisplatin/gemcitabine. In the MILES-4 study patients with non-squamous histology are
randomized, in a factorial design with 1:1:1:1 ratio, to four arms: gemcitabine (A), cisplatin/gemcitabine (B), peme-
trexed (C), cisplatin/pemetrexed (D). Two comparisons are planned: AþC vs BþD to test the role of cisplatin; AþB vs
CþD to test the role of pemetrexed. Primary endpoint of both trials is overall survival. Secondary and exploratory
endpoints include progression-free survival, response rate, toxicity, and quality of life. Conclusions: MILES-3 and
MILES-4 results will add important evidence about the role of cisplatin-based doublets and pemetrexed in the ﬁrst-line
therapy of elderly patients with advanced NSCLC.
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Introduction interval [CI], 0.84-1.05).11 OS was statistically superior for
Lung cancer is the most common cancer and the leading cause
of cancer-related deaths worldwide, with nonesmall cell lung cancer
(NSCLC) accounting for about 85% of all new diagnosis.1 Ac-
cording to an analysis by the Surveillance, Epidemiology, and End
Results (SEER) database, of 373,489 lung cancer diagnoses, more
than 50% were diagnosed in people aged  70 years, and about
15% of cases occurred in patients  80 years.2 Thus, lung cancer
represents a tumor frequently reported in the old age. Third-
generation single-agent chemotherapy became the standard of care
for elderly patients (age  70 years) affected by advanced NSCLC,
following the results of 2 randomized phase 3 trials, ELVIS (Elderly
Lung cancer Vinorelbine Italian Study) and MILES-1 (Multicenter
Italian Lung cancer in the Elderly Study).3,4 In the former trial,
single-agent vinorelbine was associated with a prolongation of
survival and a beneﬁt in quality of life (QoL) compared to best
supportive care.3 In the latter trial, combination chemotherapy with
gemcitabine plus vinorelbine did not show any signiﬁcant beneﬁt
compared to single-agent treatment.4
Platinum-based chemotherapy is the cornerstone of treatment of
advanced NSCLC patients,5,6 but it is associated with signiﬁcant
toxicity, and the evaluation of the risk/beneﬁt ratio might become
particularly critical in elderly patients. Three prospective random-
ized phase 3 trials included platinum-based doublets in elderly
patients. In these studies, the doses provided were similar to those
used for adult patients; results regarding efﬁcacy varied, but overall,
a high incidence of adverse effects was reported.7-9 A more
reasonable approach requires developing platinum-based schemes
within the population of elderly patients; thus, according to this
strategy, our cooperative group performed the MILES-2P trial.10
This study included 2 parallel phase 1 and 2 trials with the aims
of determining the recommended dose of cisplatin in combination
with gemcitabine or vinorelbine, and evaluating the feasibility of
such 2-drug combinations. We found that 60 mg/m2 is the
maximum dose of cisplatin that can be safely combined with a
standard dose of gemcitabine; however, the combination with
vinorelbine was more toxic, and the maximum dose of cisplatin that
could be safely combined with vinorelbine was 40 mg/m2. The
combination cisplatin/gemcitabine was also effective enough to
deserve phase 3 comparison vs. single-agent gemcitabine, while the
combination of cisplatin/vinorelbine was less promising. Overall,
the efﬁcacy of adding cisplatin to single-agent chemotherapy must
be demonstrated by prospective phase 3 trials dedicated to elderly
patients.
NSCLC histology represents an important variable in decision
making. Pemetrexed is currently approved in combination with
platinum as a ﬁrst-line treatment for NSCLC patients with other
than predominantly squamous cell histology as a result of the
ﬁndings reported in a subgroup analysis of a large phase 3
randomized trial. In fact, this pivotal noninferiority study was
conducted in chemotherapy-naive patients with advanced NSCLC
who received cisplatin 75 mg/m2 on day 1 and gemcitabine 1250
mg/m2 on days 1 and 8 (n ¼ 863) or cisplatin 75 mg/m2 and
pemetrexed 500 mg/m2 on day 1 (n ¼ 862) every 3 weeks, for up to
6 cycles. Overall survival (OS) for cisplatin/pemetrexed was
noninferior to cisplatin/gemcitabine (median OS, 10.3 vs. 10.3
months, respectively; hazard ratio [HR] 0.94; 95% conﬁdencecisplatin/pemetrexed vs. cisplatin/gemcitabine in patients with
adenocarcinoma (n ¼ 847; 12.6 vs. 10.9 months, respectively) and
large-cell carcinoma histology (n ¼ 153; 10.4 vs. 6.7 months,
respectively). In contrast, in patients with squamous cell histology,
there was a signiﬁcant improvement in OS with cisplatin/gemcita-
bine vs. cisplatin/pemetrexed (n ¼ 473; 10.8 vs. 9.4 months,
respectively).11 A trend toward a higher efﬁcacy of pemetrexed for
patients with nonsquamous NSCLC has also been consistently
shown in various retrospective analyses of other trials.12
The biochemical explanation of a greater efﬁcacy of pemetrexed
against nonsquamous tumors might rely on the fact that such
tumors contain low levels of thymidylate synthase (TS). Pemetrexed
inhibits multiple enzymes in the folate metabolic pathway, and TS
is the main target.13 In NSCLC cell lines, high baseline TS gene
expression levels conferred resistance to pemetrexed,14 and TS levels
were correlated to pemetrexed efﬁcacy in a variety of solid
tumors.15,16 In NSCLC, median TS gene expression is lower in
adenocarcinoma than in squamous cell carcinoma.17 A further
retrospective analysis of the registering trial comparing cisplatin/
pemetrexed to cisplatin/gemcitabine evaluated the outcomes in
elderly patients. In this study, 32.7% of the 1252 nonsquamous
patients were  65 and 12.8% were  70 years old. Patients treated
with cisplatin/pemetrexed had signiﬁcantly longer OS compared
with those treated with cisplatin/gemcitabine, with HR values
favoring pemetrexed of 0.89 (95% CI, 0.76-1.05), 0.75 (95% CI,
0.59-0.94), 0.83 (95% CI, 0.72-0.95), and 0.85 (95% CI, 0.59-
1.22) for the < 65-,  65-, < 70-, and  70-year age groups,
respectively. Dose intensity delivered and toxicities observed
for patients treated with pemetrexed were manageable and similar
between the older and younger age groups.18 However, the sug-
gested superiority of cisplatin/pemetrexed over cisplatin/gemcita-
bine has not been conﬁrmed prospectively in adult nonsquamous
NSCLC patients or in an elderly subgroup.
Objectives
The primary objective of the MILES-3 study is to test whether
the addition of cisplatin to gemcitabine prolongs OS compared to
gemcitabine alone in elderly patients with chemotherapy-naive
advanced NSCLC. Secondary objectives are to compare toxicity,
progression-free survival (PFS), objective response rate (ORR), and
QoL between the 2 arms. The MILES-3 trial is registered in
ClinicalTrials.gov (NCT01405586).
The 2 primary objectives of the MILES-4 study are, ﬁrst, to test
whether the addition of cisplatin to single-agent chemotherapy
(gemcitabine or pemetrexed) prolongs OS compared to single-agent
chemotherapy in elderly patients with nonsquamous NSCLC; and
second, to test whether pemetrexed prolongs OS compared to
gemcitabine in elderly patients with nonsquamous NSCLC. Sec-
ondary end points included comparison of toxicity, PFS, ORR, and
QoL within each planned comparison. Exploratory objective
included analyses for the identiﬁcation of prognostic and predictive
factors of the efﬁcacy of cisplatin and pemetrexed. The MILES-4
trial is registered in ClinicalTrials.gov (NCT01656551).
In both studies, OS is deﬁned as the period of time elapsing from
the date of randomization to the date of death or the date of last
follow-up for patients alive at the end of the study. PFS isClinical Lung Cancer March 2014 - 167
Figure 1 Treatment Schema of the Multicenter Italian Lung
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168 -considered to be the time from the date of randomization to the
date of progression of disease or death without progression. Patients
who are alive and whose disease has not progressed will be censored
at the last follow-up date. Objective response rate (ORR), including
complete and partial response, is assessed according to Response
Evaluation Criteria in Solid Tumors (RECIST, version 1.1).19
Intensity of adverse events will be graded according to the current
National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTC-AE, version 4.0) on a 5-point scale
(grade 1 to 5).20 QoL is measured through the European Organi-
zation for the Research and Treatment of Cancer (EORTC)
questionnaires (QLQ-C30 and QLQ-LC13).
Eligibility Criteria
In both trials, study entry is limited to patients aged> 70 years of
age with histologically or cytologically conﬁrmed metastatic
or locally advanced NSCLC and with Eastern Cooperative
Oncology Group performance status of 0 or 1. In MILES-4, only
patients with nonsquamous histology and disease staged according
to the 7th edition of the tumor, node, metastasis classiﬁcation
system are included. Adequate bone marrow, renal, and liver
function are required. Patients with asymptomatic, treated brain
metastases are eligible for trial participation.
Patients are excluded if previously treated for advanced disease
(prior adjuvant chemotherapy is permitted if it did not contain
gemcitabine and pemetrexed and if at least 6 months elapsed from
the end of adjuvant chemotherapy); if they have a history of relevant
cardiac disease or other relevant comorbidities; if other currently
active malignancies are present (with the exception of nonmelanoma
skin cancer); if they had carcinoma-in-situ of the cervix; or if they
had surgically resected prostate cancer with normal prostate-speciﬁc
antigen ﬁndings. Patients with epidermal growth factor recep-
toremutation-positive disease according to local laboratory testing
are also excluded, because for these patients, ﬁrst-line treatment
with a tyrosine-kinase inhibitor is recommended.
Informed consent will be obtained for every patient before
initiation of any trial procedure or treatment.
The partial overlapping inclusion criteria (patients with non-
squamous tumors are potentially eligible for both trials) comes
from the timing of approval: MILES-3 was approved by the
coordinating ethical committee 21 months before MILES-4.
However, there is no reason to formally exclude patients with
nonsquamous histology from MILES-3, because there might be
centers where only MILES-3 is approved and the trial remains
ethically sound. With both trials open to accrual, it is anticipated
that the accrual of patients with nonsquamous histology in
MILES-3 will slow down. Thanks to the similar study design,
however, a pooled analysis of the 2 trials for the question
regarding the efﬁcacy of cisplatin will be feasible.
Study Design and Treatment Plan
MILES-3 is an open-label, multicenter, randomized phase 3
study (Fig. 1). Eligible patients will be randomly assigned in a 1:1
ratio to 1 of the 2 following study arms: gemcitabine 1200 mg/m2
intravenously on days 1 and 8, every 3 weeks; or cisplatin 60 mg/m2
intravenously on day 1 plus gemcitabine 1000 mg/m2 intravenously
on days 1 and 8, every 3 weeks.Clinical Lung Cancer March 2014MILES-4 is an open label, multicenter, factorial randomized phase
3 study (Fig. 2). Eligible patients will be randomly assigned at a
1:1:1:1 ratio to one the following treatment arms: gemcitabine 1200
mg/m2, days 1 and 8, every 3 weeks for 6 cycles (arm A); gemcitabine
1000 mg/m2, days 1 and 8, plus cisplatin 60 mg/m2 day 1, every
3 weeks for 6 cycles (arm B); pemetrexed 500 mg/m2, day 1, every
3 weeks for 6 cycles (arm C); pemetrexed 500 mg/m2, day 1, plus
cisplatin 60 mg/m2 day 1, every 3 weeks for 6 cycles (armD). Patients
randomized in all arms receive oral folic acid (400 mg) daily plus
vitamin B12 (1000 mg) injection every 9 weeks, beginning 1 to 2
weeks before the ﬁrst dose and continuing until 3 weeks after the
last dose, and dexamethasone 4 mg orally twice daily for 3 days,
beginning on the day before chemotherapy until the day after
chemotherapy.
In both trials, before starting any study treatment, computed
tomographic scans of the brain, chest, and abdomen; 12-lead elec-
trocardiogram; and bone scan are required. Further assessments will
be performed as clinically indicated. Tumor response will be eval-
uated at the end of cycles 3 and 6 (during weeks 9 and 18). QoL
assessments will be completed by patients at baseline and at the end
of each cycle during treatment; in MILES-3, QoL will be assessed at
baseline, before day 8 of the ﬁrst cycle and at the end of the ﬁrst
3 cycles. A complete blood count and biochemistry analyses will be
performed at baseline and before any treatment administration.
Thereafter, all assessments will be performed every 12 weeks. All
patients who prematurely discontinue treatment for any reason will
be followed for survival.
Expected Results
For the planned comparison, the MILES-3 study will have 80%
power to detect a HR of death of 0.75, approximately corre-
sponding to a prolongation of median OS from 7.5 to 10 months
or an increase of the rate of patients alive at 1 year from 0.32 to
0.43. With 2-tailed alpha error 0.05, a total of 381 events (deaths)
are required. With a planned enrollment of 20 patients per month,
480 patients could be enrolled in 24 months, and data for ﬁnal
analysis should be available within 8 months after the end of
enrollment.
The study design of MILES-4 is based on 2 superiority survival
comparisons (role of cisplatin and role of pemetrexed). For each of
the 2 planned comparisons, with 2-tailed alpha error of 0.05, and 1
Figure 2 Treatment Schema of the Multicenter Italian Lung Cancer in the Elderly Study (MILES)-4
Cesare Gridelli et alinterim and 1 ﬁnal analysis, the study will have 80% power to detect
a HR of death of 0.75 (corresponding to a 3-month prolongation
of median OS based on the expectation of 9-month median OS in
the control arms) with 382 events (deaths). With a planned
enrollment of 20 patients per month, 550 patients could be enrolled
in 27.5 months, and data for ﬁnal analysis might be available within
6 months after the end of enrollment. One interim analysis will be
performed after approximately 191 events (half of the number
required for ﬁnal analysis) to refuse the null hypothesis and allow
trial interruption in case of superiority of the experimental arm. An
alpha spending function according to LaneDe Mets will be applied
with boundaries deﬁned according to O’Brian Fleming. In case the
interim analysis will produce trial stoppage for only 1 of the 2
comparisons, the study will continue with 2 arms only, those
including the winner drug.
Registration and randomization of patients in both studies is
performed centrally at the Clinical Trials Unit of the National
Cancer Institute of Naples, Italy, via a Web-based procedure that
applies a minimization technique.
Analytical Methods
The primary efﬁcacy end point analyses will be performed on the
intent-to-treat population, deﬁned as all consenting patients
randomized to trial treatment.
Analyses in the MILES-4 study will be conducted separately for
the 2 factors (efﬁcacy of the addition of cisplatin and relative efﬁcacy
of pemetrexed vs. gemcitabine).
Statistical signiﬁcance of differences in OS and PFS between
treatment arms will be tested by the log-rank test adjusted by the
stratiﬁcation factors used at randomization. Kaplan-Meier curves
will be created, with median estimates and 95% CIs provided for
each treatment arm. Cox modeling will be used for multivariable
analysis with baseline variables involved in the minimization pro-
cedure as covariates.In each comparison, ORR is deﬁned as the rate of patients who
will experience a complete or partial response according to RECIST
(responders). Patients who do not experience a complete or partial
response will be classiﬁed as non-responders.
For each patient and for each type of toxicity, the worst degree of
toxicity experienced during treatment will be used for the analysis.
Two sets of statistical analyses will be performed to compare
toxicity. In the ﬁrst set, the whole pattern of toxicity (each grade)
will be considered for each item; analysis will be done by a linear
rank test. In the second set, toxicity will be deﬁned as severe (mostly
including grade 3 or higher) and not severe (mostly including grades
up to 2), and analysis will be performed by Chi square or Fisher’s
exact test as appropriate.
The QoL changes from baseline evaluation and the proportion of
patients with improvement, decline, or no change in their health-
related QoL will be described.
Conclusion
The MILES-3 and MILES-4 studies are designed to examine the
role of cisplatin-based doublets and pemetrexed in the ﬁrst-line
therapy of elderly patients with advanced NSCLC. In the MILES-3
trial, patients with all NSCLC histologies will be randomized to
receive either single-agent gemcitabine or cisplatin plus gemcitabine.
In the MILES-4 trial, patients with nonsquamous NSCLC will be
randomized to receive a single agent (gemcitabine or pemetrexed)
or cisplatin doublets (cisplatin/gemcitabine or cisplatin/pemetrexed).
The primary end point of both trials is OS, and a number of
secondary and exploratory objectives will also be assessed.Acknowledgments
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